User profiles for C. Brayne
Professor Carol BrayneCambridge Institute of Public Health Verified email at cam.ac.uk Cited by 201431 |
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
The number of older people, including those living with dementia, is rising, as younger age
mortality declines. However, the age-specific incidence of dementia has fallen in many …
mortality declines. However, the age-specific incidence of dementia has fallen in many …
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a …
…, LN Boyers, M Brainin, M Brauer, CEG Brayne… - The lancet, 2015 - thelancet.com
Background Up-to-date evidence about levels and trends in disease and injury incidence,
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, …
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, …
Alzheimer's disease
An estimated 24 million people worldwide have dementia, the majority of whom are thought
to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health …
to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health …
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
…, R Bourne, M Boussinesq, T Braithwaite, C Brayne… - The lancet, 2012 - thelancet.com
Background Measuring disease and injury burden in populations requires a composite metric
that captures both premature mortality and the prevalence and severity of ill-health. The …
that captures both premature mortality and the prevalence and severity of ill-health. The …
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
…, R Bourne, M Boussinesq, T Braithwaite, C Brayne… - The lancet, 2012 - thelancet.com
Background Non-fatal health outcomes from diseases and injuries are a crucial consideration
in the promotion and monitoring of individual and population health. The Global Burden of …
in the promotion and monitoring of individual and population health. The Global Burden of …
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
…, J Hardy, MCD Naranjo, P Bosco, R Clarke, C Brayne… - Nature …, 2013 - nature.com
Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous
studies; however, a large portion of the genetic risk for this disease remains unexplained. …
studies; however, a large portion of the genetic risk for this disease remains unexplained. …
Global prevalence of dementia: a Delphi consensus study
Background 100 years after the first description, Alzheimer's disease is one of the most
disabling and burdensome health conditions worldwide. We used the Delphi consensus method …
disabling and burdensome health conditions worldwide. We used the Delphi consensus method …
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features
seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter …
seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter …
[HTML][HTML] Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
Background Given the projected trends in population ageing and population growth, the
number of people with dementia is expected to increase. In addition, strong evidence has …
number of people with dementia is expected to increase. In addition, strong evidence has …
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD)
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …